Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus.

Published on Apr 20, 2021in Cancer Treatment Reviews8.885
· DOI :10.1016/J.CTRV.2021.102206
Barbara Alicja Jereczek-Fossa36
Estimated H-index: 36
Giulia Marvaso14
Estimated H-index: 14
+ 33 AuthorsPiet Ost41
Estimated H-index: 41
Abstract Background and purpose Between 30% and 47% of patients treated with definitive radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up. Re-irradiation with stereotactic body RT (SBRT) is emerging as a feasible and safe therapeutic option. However, no consensus or guidelines exist on this topic. The purpose of this ESTRO ACROP project is to investigate expert opinion on salvage SBRT for intraprostatic relapse after RT. Materials and Methods A 40-item questionnaire on salvage SBRT was prepared by an internal committee and reviewed by a panel of leading radiation oncologists plus a urologist expert in prostate cancer. Following the procedure of a Delphi consensus, 3 rounds of questionnaires were sent to selected experts on prostate re-irradiation. Results Among the 33 contacted experts, 18 (54.5%) agreed to participate. At the end of the final round, participants were able to find consensus on 14 out of 40 questions (35% overall) and major agreement on 13 questions (32.5% overall). Specifically, the consensus was reached regarding some selection criteria (no age limit, ECOG 0-1, satisfactory urinary flow), diagnostic procedures (exclusion of metastatic disease, SBRT target defined on the MRI) and therapeutic approach (no need for concomitant ADT, consideration of the first RT dose, validity of Phoenix criteria for salvage SBRT failure). Conclusion While awaiting the results of ongoing studies, our ESTRO ACROP Delphi consensus may serve as a practical guidance for salvage SBRT. Future research should address the existing disagreements on this promising approach.
📖 Papers frequently viewed together
25 Citations
208 Citations
11 Citations
#1Luca F. Valle (UCLA: University of California, Los Angeles)H-Index: 3
#1Luca F. Valle (UCLA: University of California, Los Angeles)H-Index: 8
Last. Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 19
view all 17 authors...
Abstract Context Management of locally recurrent prostate cancer after definitive radiotherapy remains controversial due to the perceived high rates of severe genitourinary (GU) and gastrointestinal (GI) toxicity associated with any local salvage modality. Objective To quantitatively compare the efficacy and toxicity of salvage radical prostatectomy (RP), high-intensity focused ultrasound (HIFU), cryotherapy, stereotactic body radiotherapy (SBRT), low–dose-rate (LDR) brachytherapy, and high-dose...
14 CitationsSource
#1Fernando MunozH-Index: 11
#2Francesco FioricaH-Index: 16
Last. Mariangela Massaccesi (CUA: The Catholic University of America)H-Index: 16
view all 15 authors...
Abstract Aims The best therapeutic approach for local relapses of previously irradiated prostate cancer (PC) is still not defined. Re-irradiation (Re-I) could offer a chance of cure for highly selected patients, although high quality evidences are lacking. The aim of our study is to provide a literature review on efficacy and safety of Re-I. Methods Only studies where Re-I field overlaps with previous radiotherapy were considered. To determine 2 and 4 years overall mortality (OM), 2 and 4 years ...
2 CitationsSource
#1Amar U. Kishan (UCLA: University of California, Los Angeles)H-Index: 19
#2Nicholas G. Nickols (UCLA: University of California, Los Angeles)H-Index: 23
Last. Daniel E. Spratt (UM: University of Michigan)H-Index: 50
view all 3 authors...
Radiotherapy has curative potential for patients with newly diagnosed localized prostate cancer and biochemical recurrence after radical prostatectomy, and can offer durable treatment responses for patients with oligometastatic disease. The success of radiotherapy in these settings relies on an accurate understanding of the extent of disease that is present and the precise anatomic localization of sites of disease. In this mini review, we provide an overview of recent data evaluating the role of...
3 CitationsSource
#1Mark T. Corkum (London Health Sciences Centre)H-Index: 5
#2Lucas C. Mendez (London Health Sciences Centre)H-Index: 10
Last. Glenn Bauman (London Health Sciences Centre)H-Index: 53
view all 6 authors...
Abstract Purpose Reirradiation (re-RT) using external beam radiotherapy (EBRT) is a novel salvage strategy for local failure in prostate cancer. We performed a systematic review describing oncologic and toxicity outcomes for salvage EBRT/stereotactic radiotherapy (SBRT) re-RT. Materials and Methods A PROSPERO-registered (#XXX) systematic review, meta-analysis and meta-regression was conducted using PRISMA guidelines. PubMed and EMBASE were searched from inception through September 2019. Outcome ...
7 CitationsSource
#1Sarah Bergamin (USYD: University of Sydney)H-Index: 4
#2Thomas Eade (USYD: University of Sydney)H-Index: 27
Last. George Hruby (USYD: University of Sydney)H-Index: 26
view all 12 authors...
Abstract Purpose To report the feasibility, toxicity, and preliminary outcomes (metabolic and biochemical) of 68Ga-PSMA PET/CT directed focal prostate re-irradiation using linear accelerator (LINAC) based stereotactic body radiation treatment (SBRT). Methods and Materials From March 2016 to March 2019 25 patients were enrolled in a prospective single institution trial (XXX). Eligibility criteria included patients with biopsy proven isolated prostate recurrence following definitive irradiation, w...
6 CitationsSource
#1Dario Zerini (IEO: European Institute of Oncology)H-Index: 17
#2Barbara Alicja Jereczek-Fossa (IEO: European Institute of Oncology)H-Index: 3
Last. Filippo Alongi (University of Brescia)H-Index: 15
view all 14 authors...
PURPOSE We herein present the results of the first Italian Association of Radiotherapy and Clinical Oncology (AIRO) survey regarding salvage external beam re-irradiation of local prostate cancer relapse named PROLAPSE. METHODS A questionnaire with 12 items was administered to the 775 Italian radiation oncologist members of the AIRO. RESULTS One hundred of the members completed the survey. The survey highlighted that 59% of the participants are currently performing prostate re-EBRT, while nearly ...
4 CitationsSource
#1Francesco CucciaH-Index: 7
#2Luca NicosiaH-Index: 11
Last. Filippo Alongi (University of Brescia)H-Index: 15
view all 11 authors...
BACKGROUND AND OBJECTIVE: The optimal management of prostate cancer (PC) recurrences after definitive or postoperative radiotherapy (RT) is still controversial. The aim of the present retrospective study was to report the preliminary clinical results and toxicity of a mono-institutional series of patients re-irradiated with linac-based SBRT in recurrent prostate cancer. METHODS: Inclusion criteria were previous definitive or adjuvant/salvage RT, evidence of biochemical recurrence and radiologica...
6 CitationsSource
#1Gianluca Ingrosso (University of Rome Tor Vergata)H-Index: 13
#2Carlotta Becherini (UniFI: University of Florence)H-Index: 9
Last. Beatrice Detti (UniFI: University of Florence)H-Index: 20
view all 15 authors...
Abstract Context Different nonsurgical therapeutic strategies can be adopted for intraprostatic relapse of prostate cancer after primary radiotherapy, including re-irradiation (with brachytherapy [BT] or external beam radiotherapy [EBRT]), high-intensity focused ultrasound (HIFU), and cryotherapy. The main issues to consider when choosing nonsurgical salvage local therapies are local tumor control and significant genitourinary toxicity. Objective To conduct a systematic review and meta-analysis ...
20 CitationsSource
Abstract Purpose /Objectives: We evaluated the use of HDR-like stereotactic body radiation therapy (SBRT) retreatment for biopsy proven local persistence in the prostate post-radiotherapy (RT), evaluating efficacy and toxicity. Methods and Materials From 2009–2018, 50 patients with biopsy-proven recurrent prostate cancer >2 years after prior treatment were retreated with an HDR-like dose of 3400 cGy over 5 fractions. Previous radiotherapy dose measured 75.6 Gy (64.8–81.0) and median salvage inte...
17 CitationsSource
#1Joyce G. R. Bomers (Radboud University Nijmegen)H-Index: 12
#2Christiaan G. Overduin (Radboud University Nijmegen)H-Index: 7
Last. Jurgen J. Fütterer (UT: University of Twente)H-Index: 59
view all 7 authors...
Abstract Purpose To evaluate safety, quality of life (QoL), and local cancer control after focal salvage MR imaging–guided cryoablation in patients with local recurrence of prostate cancer (PCa) after radiotherapy. Materials and Methods A retrospective, single-center study was performed in 62 patients with radiorecurrent PCa who underwent MR imaging–guided cryoablation since May 2011 with a follow-up ≥12 months in December 2017. Rates and descriptions of adverse events were reported. Ablation co...
8 CitationsSource
Cited By1
#1P. Graff (Curie Institute)
Last. Gilles Crehange (Curie Institute)H-Index: 10
view all 2 authors...
Resume null null Encore emergente il y a quelques annees, la radiotherapie stereotaxique s’est imposee comme une option valide de prise en charge du cancer localise de la prostate. Les proprietes intrinseques de l’adenocarcinome prostatique (faible rapport α/β) en font un excellent candidat. Nous proposons une revue des donnees de la litterature qui valident l’utilisation de cette technique emergente avec une mise en perspective des resultats, de leurs limites et des axes de developpement. La te...